Details for Patent: 11,596,614
✉ Email this page to a colleague
Which drugs does patent 11,596,614 protect, and when does it expire?
Patent 11,596,614 protects LIVDELZI and is included in one NDA.
This patent has fifty-seven patent family members in twenty-eight countries.
Drugs Protected by US Patent 11,596,614
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences Inc | LIVDELZI | seladelpar lysine | CAPSULE;ORAL | 217899-001 | Aug 14, 2024 | RX | Yes | Yes | 11,596,614 | ⤷ Subscribe | TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,596,614
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2015231232 | ⤷ Subscribe | |||
| Australia | 2017274293 | ⤷ Subscribe | |||
| Brazil | 112016020260 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
